Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Theravance Biopharma News

    8,85 € +1,14% +0,10 €
    08:09:37 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1137V
    ISIN: KYG8807B1068
    US-Symbol: TBPH
    Typ: Aktie

    Theravance Biopharma News

    10.04.24 - PR Newswire
    Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
    Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic ...
    26.02.24 - PR Newswire
    Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire
    22.02.24 - PR Newswire
    Theravance Biopharma to Participate in an Upcoming Investor Conference
    Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire
    14.02.24 - PR Newswire
    Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
    Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 PR Newswire
    05.01.24 - PR Newswire
    Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
    Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) PR ...
    21.12.23 - PR Newswire
    Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
    Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors PR Newswire
    18.12.23 - PR Newswire
    Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
    Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference PR Newswire
    16.11.23 - PR Newswire
    Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System
    Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System PR Newswire
    15.11.23 - PR Newswire
    Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference
    Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference PR Newswire
    13.11.23 - PR Newswire
    Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
    Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary ...
    13.11.23 - PR Newswire
    Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
    Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary ...
    07.11.23 - PR Newswire
    Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
    Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire
    29.08.23 - PR Newswire
    Theravance Biopharma to Participate in an Upcoming Investor Conference
    Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire
    28.08.23 - PR Newswire
    Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
    Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders PR Newswire
    07.08.23 - PR Newswire
    Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
    Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire
    24.07.23 - PR Newswire
    Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023
    Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023 PR Newswire
    09.05.23 - PR Newswire
    Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy
    Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with ...
    08.05.23 - PR Newswire
    Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
    Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire
    24.04.23 - PR Newswire
    Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023
    Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023 PR Newswire
    11.04.23 - PR Newswire
    Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors
    Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors PR Newswire

    Newssuche

    Videos

    newspaper
    09:10 Uhr
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: UH45D5 Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »